Chronic obstructive pulmonary disease (COPD) patients with chronic respiratory failure fare well with noninvasive home ventilation treatment, which cuts the risk of death and healthcare utilization, a study has found.
Gastroesophageal reflux disease (GERD) may predispose patients to developing other diseases, as reported in a study. For the most part, it puts the whammy on chronic obstructive pulmonary disorder, doubling exacerbations, and raises the risk of oesophageal adenocarcinoma.
A pulmonary rehabilitation programme for chronic obstructive pulmonary disease (COPD) yields sustained improvements in anxiety and quality of life of patients over 2 years, a study has shown. However, the positive changes in dyspnoea, depression, and stress symptoms may only last short term.
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.
In the management of chronic obstructive pulmonary disease (COPD), fewer men than women utilize guideline-recommended, non-pharmacological interventions, such as smoking cessation and physical activity programmes, according to a study. Moreover, active smoking is a risk factor for low uptake.
A once-daily triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; ICS/LAMA/LABA*) in a single inhaler significantly reduces the risk of all-cause mortality compared with a dual therapy of UMEC/VI (LAMA/LABA) in chronic obstructive pulmonary disease (COPD) patients with a history of moderate or severe exacerbations, confirm the latest results of the IMPACT** study.
Both antibiotics and systemic corticosteroids reduce treatment failure rates in patients with chronic obstructive pulmonary disease (COPD), regardless of severity of exacerbations, according to a systematic review and meta-analysis of randomized trials.
Use of antibiotics and systemic corticosteroids can help decrease treatment failure in adults with mild-to-severe exacerbation of chronic obstructive pulmonary disease (COPD), results of a systematic review and meta-analysis have shown.
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.